Trial Profile

mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms (TACTIC-E)

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 02 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ambrisentan (Primary) ; Dapagliflozin (Primary) ; EDP-1815 (Primary)
Indications COVID 2019 infections
Focus Therapeutic Use
Acronyms TACTIC-E

Most Recent Events

26 Jul 2023 Status changed from recruiting to completed.
04 Jan 2022 According to an Evelo Biosciences media release, interim safety and futility analysis of 375 patients (125 patients from each arm) is expected in 1H 2022.
28 Oct 2021 According to an Evelo Biosciences media release, the company is progressing recruiting with the addition of clinical study sites in the UK, Brazil, India, and Mexico.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com